Adjuvant therapies for very young women with early stage breast cancer

Breast

Volumn 20, Issue SUPPL. 3, 2011, Pages

  Freedman, Rachel A ^a   Partridge, Ann H ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Adjuvant therapy; Breast cancer; Chemotherapy; Fertility; Premature menopause; Young women

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EXEMESTANE; GOSERELIN; PROGESTERONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB; TRIPTORELIN; ZOLEDRONIC ACID;

ADJUVANT THERAPY; AGE; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; DELAYED DIAGNOSIS; DISEASE FREE SURVIVAL; HEALTH CARE ACCESS; HEALTH CARE NEED; HUMAN; MAMMOGRAPHY; MEDICAL DECISION MAKING; META ANALYSIS (TOPIC); NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; TREATMENT OUTCOME;

EID: 80054850202     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/S0960-9776(11)70313-7     Document Type: Article

References (56)

1. American Cancer Society Breast Cancer Facts and Figures 2009-2010 Accessed March 11, 2011. http://www.cancer.0rg/acs/groups/content/@nho/documents/document/f861009final90809pdf.pdf.
2. American Cancer Society Global Cancer Facts and Figures Accessed March 11, 2011. http://www.cancer.0rg/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-027766.pdf.
3. Porter P "Westernizing" women's risks? Breast cancer in lower-income countries. N Engl J Med 2008, 358:213-216. 2nd edn.
4. SEER Cancer Statistics Review, 1997-2007. 5-Year relative survival (percent) 1999-2006 by age at diagnosis Accessed March 11,2011. http://seer.cancer.gov/csr/1975_2007/browse_csr.php?section=4&page=sect_04_table.l4.html#table4.
5. Xiong Q, Valero V, Kau V, et al. Female patients with breast carcinoma age 30 years and younger have a poor prognosis: the M.D. Anderson Cancer Center experience. Cancer 2001, 92:2523-2528.
6. Zabicki K, Colbert JA, Dominguez FJ, et al. Breast cancer diagnosis in women
7. Sidoni A, Cavaliere A, Bellezza G, Scheibel M, Bucciarelli E Breast cancer in young women: clinicopathological features and biological specificity. Breast 2003, 12:247-250.
8. Walker RA, Lees E, Webb MB, Dearing SJ Breast carcinomas occurring in young women (<35 years) are different. BrJ Cancer 1996, 74:1796-1800.
9. Sariego J Breast cancer in the young patient. Am Surg 2010, 76:1397-1400.
10. Ruddy KJ, Gelber S, Tamimi R, et al. 2009 American Society of Clincal Oncology MeetingJ. Clin Oncol 2009, 27(Suppl):15s. abstract 6608.
11. Barber MD, Jack W, Dixon JM Diagnostic delay in breast cancer. BrJ Surg 2004, 91:49-53.
12. Shavers VL, Harlan LC, Stevens JL Racial/ethnic variation in clinical presentation, treatment, and survival among breast cancer patients under age 35. Cancer 2003, 97:134-147.
13. Adami HO, Malker B, Holmberg L, Persson I, Stone B The relation between survival and age at diagnosis in breast cancer. NEnglJMed 1986, 315:559-563.
14. Jayasinghe UW, Taylor R, Boyages J Is age at diagnosis an independent prognostic factor for survival following breast cancer?. Aust NZJ Surg 2005, 75:762-767.
15. Han W, Kim SW, Park IA, et al. Young age: an independent risk factor for disease-free survival in women with operable breast cancer. BMC Cancer 2004, 4:82.
16. Han W, Kang SY Relationship between age at diagnosis and outcome of premenopausal breast cancer: age less than 35 years is a reasonable cut-off for defining young age-onset breast cancer. Breast Cancer Res Treat 2010, 119:193-200.
17. Goldhirsch A, Gelber RD, Yothers G, et al. Adjuvant therapy for very young women with breast cancer: need for tailored treatments. J Natl Cancer Inst Monogr 2001, 44-51.
18. Muscolino G, Villani C, Bedini AV, Luini A, Salvadori B Young age is not an ominous prognostic factor in breast cancer patients. Tumori 1987, 73:233-235.
19. Anderson BO, Senie RT, Vetto JT, Wong GY, McCormick B, Borgen PI Improved survival in young women with breast cancer. Ann Surg Oncol 1995, 2:407-415.
20. Henderson IC, Patek AJ Are breast cancers in young women qualitatively distinct?. Lancet 1997, 349:1488-1489.
21. Shak S, Baehner FL, Stein M, et al. Quantitative gene expression analysis in a large cohort of estrogen receptor-positive breast cancer: characterization of the tumor profiles in younger patients (<=40yrs) and in older patients (>=70yrs). San Antonio Breast Cancer Symposium, December 10, 2010.
22. Ahn SH, Son BH, Kim SW, et al. Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea - a report from the Korean Breast Cancer Society. J Clin Oncol 2007, 25:2360-2368.
23. Elmore JG, Moceri VM, Carter D, Larson EB Breast carcinoma tumor characteristics in black and white women. Cancer 1998, 83:2509-2515.
24. Elledge RM, Clark GM, Chamness GC, Osborne CK Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst 1994, 86:705-712.
25. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006, 295:2492-2502.
26. Preventive Services Task Force Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009, 151:716-726.
27. Harris VJ, Jackson VP Indications for breast imaging in women under age 35 years. Radiology 1989, 172:445-448.
28. Di Nubila B, Cassano E, Urban LA, et al. Radiological features and pathological-biological correlations in 348 women with breast cancer under 35 years old. Breast 2006, 15:744-753.
29. Houssami N, Irwig L, Simpson JM, McKessar M, Blome S, Noakes J Sydney Breast Imaging Accuracy Study: Comparative sensitivity and specificity of mammography and sonography in young women with symptoms. AJR Am J Roentgenol 2003, 180:935-940.
30. Kb lb TM, Lichy J, Newhouse JH Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27,825 patient evaluations. Radiology 2002, 225:165-175.
31. Morrow M, Wong S, Venta L The evaluation of breast masses in women younger than forty years of age. Surgery 1998, 124:634-640. discussion 40-1.
32. Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N EnglJ Med 2004, 351:427-437.
33. Partridge AH, Hughes ME, Wong Y, et al. The effect of age on delay in diagnosis and stage of breast cancer. American Society of Clinical Oncology 2010 Meeting. J Clin Oncol 2010, 28(Suppl):15s. (abstract 1580).
34. Rajakariar R, Walker RA Pathological and biological features of mammographi-cally detected invasive breast carcinomas. BrJ Cancer 1995, 71:150-154.
35. Ring AE, Smith IE, Ellis PA Breast cancer and pregnancy. Ann Oncol 2005, 16:1855-1860.
36. Pavlidis NA Coexistence of pregnancy and malignancy. Oncologist 2002, 7:279-287.
37. Woo JC, Yu T, Hurd TC Breast cancer in pregnancy: a literature review. Arch Surg 2003, 138:91-98. discussion 9.
38. Freedman RA, He Y, Winer EP, Keating NL Trends in racial and age disparities in definitive local therapy of early-stage breast cancerJC/in. Oncol 2009, 27:713-719.
39. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717.
40. De Laurentiis M, Cancello G, D'Agostino D, et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials.;. Clin Oncol 2008, 26:44-53.
41. Partridge AH, Gelber S, Piccart MJ, et al. The Effect of Age on Breast Cancer Outcomes in Women with HER2-positive Breast Cancer; Results from the HERA trial. San Antonio Breast Cancer Symposium, December 11, 2010.
42. Kroman N, Jensen MB, Wohlfahrt J, Mouridsen HT, Andersen PK, Melbye M Factors influencing the effect of age on prognosis in breast cancer: population based study. BMJ 2000, 320:474-478.
43. Boccardo F, Rubagotti A, Amoroso D, et al. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. boccardo@hp380.ist.unige.it. J Clin Oncol 2000, 18:2718-2727.
44. Jonat W, Kaufmann M, Sauerbrei W, et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 2002, 20:4628-4635.
45. Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial. Scottish Cancer Trials Breast Group and ICRF Breast Unit, Guy's Hospital, London. Lancet 1993, 341:1293-1298.
46. Jakesz R, Hausmaninger H, Kubista E, et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer - Austrian Breast and Colorectal Cancer Study Group Trial, 5. J Clin Oncol 2002, 20:4621-4627.
47. Swain SM, Jeong JH, Geyer CE, et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N EnglJ Med 2010, 362:2053-2065.
48. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N EnglJ Med 2009, 360:679-691.
49. Coleman RE, Thorpe HC, Cameron D, et al. Adjuvant treatment with zoledronic acid in stage II/III breast cancer. The AZURE trial (BIG 01/04). San Antonio Breast Cancer Symposium, December 10, 2010.
50. Partridge AH, Wang PS, Winer EP, Avorn J Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 2003, 21:602-606.
51. Goss PE, Ingle JN, Martino S, et al. Outcomes of women who were premenopausal at diagnosis of early stage breast cancer in the NCIC CTG MA17 trial. San Antonio Breast Cancer Symposium, December 10, 2009 (abstract 13).
52. Partridge AH, Goldhirsch A, Gelber S, Gelber RD Breast cancer in young women. Diseases of the Breast 2010, Lippincott Williams & Wilkins, Philadelphia. 4th edn. Harris, Lippman, Morrow, Osborne (Eds.).
53. Ganz PA, Greendale GA, Petersen L, Kahn B, Bower JE Breast cancer in younger women: reproductive and late health effects of treatment. J Clin Oncol 2003, 21:4184-4193.
54. Dunn J, Steginga SK Young women's experience of breast cancer: defining young and identifying concerns. Psychooncology 2000, 9:137-146.
55. Partridge AH, Gelber S, Peppercorn J, et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol 2004, 22:4174-4183.
56. Leining MG, Gelber S, Rosenberg R, Przypyszny M, Winer EP, Partridge AH Menopausal-type symptoms in young breast cancer survivors. Ann Oncol 2006, 17:1777-1782.